Add like
Add dislike
Add to saved papers

Dipeptidylpeptidase IV of Streptococcus suis degrades the porcine antimicrobial peptide PR-39 and neutralizes its biological properties.

Microbial Pathogenesis 2018 September
Streptococcus suis is a major swine pathogen causing pathologies such as meningitis, sepsis, endocarditis, and arthritis. Several surface-bound and secreted proteases produced by S. suis have been identified and proposed as virulence factors. PR-39 is a proline/arginine-rich antimicrobial peptide produced by porcine leucocytes. In addition to play a role in innate immunity, this peptide possesses immunomodulatory properties. In this study, we hypothesized that proteases produced by S. suis inactivate PR-39. Most strains of S. suis tested were relatively resistant to PR-39, with minimal inhibitory concentration (MIC) values ≥ 200 μg/ml. The proteolytic cleavage of PR-39 by recombinant subtilisin-like protease and dipeptidylpeptidase IV (DPPIV) of S. suis was assessed by SDS-PAGE. While PR-39 was not cleaved by the subtilisin-like protease, it was time-dependently degraded by DPPIV. Whole cells of S. suis also degraded PR-39. When S. suis was grown in a culture medium supplemented with recombinant DPPIV, its susceptibility to PR-39 was decreased. Activation of brain microvascular endothelial cells with PR-39 resulted in an increased secretion of the chemokine interleukin-8 (IL-8) thus confirming the immunomodulatory activity of this porcine antimicrobial peptide. However, a pre-treatment of PR-39 with DPPIV completely neutralized the increased IL-8 secretion. In this study, we showed that DPPIV produced by S. suis can degrade PR-39 and neutralize its antibacterial and immunomodulatory properties. This may allow survival of S. suis in the central nervous system by resisting to killing by this antimicrobial peptide and delaying the recruitment of phagocytic cells such as neutrophils to the site of infection.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app